Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Crinetics receives SBIR grants from NIDDK
November 2017
SHARING OPTIONS:

SAN DIEGO—The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) recently awarded two new Small Business Innovation Research grants to rare disease company Crinetics Pharmaceuticals Inc. that could total $2.4 million. The grants consist of a Phase 1 grant for $300,000 and a Fast Track grant for up to $2.1 million, and they will be used to support the discovery of novel small-molecule drugs for Cushing's disease and for the development of Crinetics’ nonpeptide, oral somatostatin agonists for congenital hyperinsulinemia, respectively.
 
“We are delighted with the NIH’s continuing support of our programs to develop new drugs for patients with rare endocrine disorders,” said Dr. Stephen Betz, Crinetics' founder and vice president of Biology. “These awards will enable us to advance our efforts in both hyperinsulinemia and Cushing’s disease, expanding our pipeline to include these diseases with significant unmet medical needs and bring these treatments to the patients who need them.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.